Patient and disease characteristics
Characteristic . | Data . |
|---|---|
| Conditioning regimens, % | |
| 2 Gy TBI | 6 |
| Fludarabine + 2 Gy TBI | 22 |
| CY + at least 12 Gy TBI | 29 |
| BU + CY | 43 |
| Postgrafting immunosuppression, % | |
| CSP + MMF | 18 |
| CSP + MTX | 82 |
| Donor type, % | |
| Related donor | 58 |
| Unrelated donor | 42 |
| Diagnoses, % | |
| AML | 27 |
| CML | 20 |
| MDS | 19 |
| ALL | 10 |
| NHL | 9 |
| MM | 6 |
| CLL | 4 |
| HD | 2 |
| Nonmalignant hematologic* | 3 |
| Disease risk group, %† | |
| High | 41 |
| Low | 59 |
| Age at transplantation | |
| Median (range), y | 44.8 (0.8-72.7) |
| Preceding myeloablative HCT, % | |
| Allogeneic | 2 |
| Failed autologous | 6 |
| Planned autologous | 5 |
| Hematopoietic cell source, % | |
| G-PBMC | 71 |
| Marrow | 29 |
| Male/female, % | |
| Patients | 56/44 |
| Donors | 51/49 |
Characteristic . | Data . |
|---|---|
| Conditioning regimens, % | |
| 2 Gy TBI | 6 |
| Fludarabine + 2 Gy TBI | 22 |
| CY + at least 12 Gy TBI | 29 |
| BU + CY | 43 |
| Postgrafting immunosuppression, % | |
| CSP + MMF | 18 |
| CSP + MTX | 82 |
| Donor type, % | |
| Related donor | 58 |
| Unrelated donor | 42 |
| Diagnoses, % | |
| AML | 27 |
| CML | 20 |
| MDS | 19 |
| ALL | 10 |
| NHL | 9 |
| MM | 6 |
| CLL | 4 |
| HD | 2 |
| Nonmalignant hematologic* | 3 |
| Disease risk group, %† | |
| High | 41 |
| Low | 59 |
| Age at transplantation | |
| Median (range), y | 44.8 (0.8-72.7) |
| Preceding myeloablative HCT, % | |
| Allogeneic | 2 |
| Failed autologous | 6 |
| Planned autologous | 5 |
| Hematopoietic cell source, % | |
| G-PBMC | 71 |
| Marrow | 29 |
| Male/female, % | |
| Patients | 56/44 |
| Donors | 51/49 |
n = 1055.
TBI indicates total body irradiation; CY, cyclophosphamide; BU, busulfan; CSP, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndromes; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; HCT, hematopoietic cell transplantation; and G-PBMC, granulocyte colony stimulating factor-mobilized peripheral blood mononuclear cells.
Immunodeficiency syndrome, chronic granulomatous disease, congential dyserythropoietic anemia, paroxysmal nocturnal hemoglobinuria, polycythemia vera, thalassemic syndrome, and sickle cell anemia.
Low indicates acute leukemia in first remission, CML in first chronic phase, MDS-refractory anemia, or nonmalignant hematologic disease; while high indicates all other diagnoses.